Hybio Pharmaceutical (300199) — Net Asset Momentum
Hybio Pharmaceutical (300199) recorded a net asset momentum of -23.8% as of December 2024, with net assets of CN¥597.05 Million CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See 300199 net asset value for net asset value and shareholders' equity analysis.
YoY Momentum
Current Net Assets
Years of Data
Country
Hybio Pharmaceutical Net Asset Momentum (2007–2024)
This chart tracks Hybio Pharmaceutical's year-over-year net asset growth across 18 annual reporting periods from 2007 to 2024. The most recent momentum reading is -23.8%, with net assets of CN¥597.05 Million CNY as of December 2024. For live market cap and overall valuation, see Hybio Pharmaceutical stock valuation.
Annual Net Asset History for Hybio Pharmaceutical (2007–2024)
The table below shows the complete annual net asset history for Hybio Pharmaceutical from 2007 to 2024, covering 18 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. Check Hybio Pharmaceutical (300199) tangible equity ratio to evaluate the tangible quality of the company's equity base.
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | CN¥597.05 Million | CN¥3.01 Billion | CN¥2.41 Billion | ▼ -23.8% |
| 2023 | CN¥783.21 Million | CN¥3.28 Billion | CN¥2.49 Billion | ▼ -39.6% |
| 2022 | CN¥1.30 Billion | CN¥3.61 Billion | CN¥2.31 Billion | ▼ -21.3% |
| 2021 | CN¥1.65 Billion | CN¥3.91 Billion | CN¥2.26 Billion | ▼ -1.8% |
| 2020 | CN¥1.68 Billion | CN¥4.02 Billion | CN¥2.34 Billion | ▼ -24.9% |
| 2019 | CN¥2.23 Billion | CN¥4.72 Billion | CN¥2.49 Billion | ▼ -34.2% |
| 2018 | CN¥3.39 Billion | CN¥5.66 Billion | CN¥2.27 Billion | ▼ -12.7% |
| 2017 | CN¥3.88 Billion | CN¥5.30 Billion | CN¥1.41 Billion | ▲ +7.8% |
| 2016 | CN¥3.60 Billion | CN¥4.46 Billion | CN¥852.42 Million | ▲ +36.7% |
| 2015 | CN¥2.64 Billion | CN¥3.55 Billion | CN¥908.68 Million | ▲ +103.5% |
| 2014 | CN¥1.30 Billion | CN¥1.70 Billion | CN¥401.32 Million | ▲ +15.3% |
| 2013 | CN¥1.12 Billion | CN¥1.29 Billion | CN¥164.48 Million | ▲ +10.6% |
| 2012 | CN¥1.02 Billion | CN¥1.12 Billion | CN¥107.42 Million | ▲ +4.1% |
| 2011 | CN¥976.09 Million | CN¥1.04 Billion | CN¥59.56 Million | ▲ +440.5% |
| 2010 | CN¥180.59 Million | CN¥212.89 Million | CN¥32.30 Million | ▲ +41.4% |
| 2009 | CN¥127.74 Million | CN¥182.47 Million | CN¥54.73 Million | ▲ +28.7% |
| 2008 | CN¥99.23 Million | CN¥136.55 Million | CN¥37.32 Million | ▲ +103.8% |
| 2007 | CN¥48.70 Million | CN¥58.24 Million | CN¥9.54 Million | — |